Hydroxychloroquine (All indications except Antiphospholipid Syndrom)

Neonatal disorders (as a whole)

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S13773
R53891
Baalbaki, 2020 Neonatal composite (fetal death, NICU, neonatal death, intraventricular hemorrhage, sepsis, necrotizing enterocolitis, ...) during pregnancy (anytime or not specified) retrospective cohort unexposed, sick Adjustment: No Indication HCQ: Systemic lupus erythematosus (SLE) 0.62 [0.25;1.57] C 18/47   15/30 33 47
ref
S13713
R53412
Mollerach, 2019 Neonatal complications (NOS) throughout pregnancy retrospective cohort unexposed, sick Adjustment: No Indication HCQ: Rheumatic diseases as a whole (Systemic lupus erythematosus, Rheumatoid arthritis, Sjogren's syndrome...) 3.87 [0.07;205.70] C 0/12   0/45 0 12
ref
S13651
R52961
Cooper (controls exposed to TNF-I), 2014 Neonatal complications 1st trimester retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No Indication HCQ: Rheumatic diseases as a whole (Systemic lupus erythematosus, Rheumatoid arthritis, Sjogren's syndrome...) 1.01 [0.32;3.20] C
excluded (control group)
14/194   4/56 18 194
ref
S13652
R52991
Cooper (controls unexposed, sick), 2014 Neonatal complications 1st trimester retrospective cohort (claims database) unexposed, sick Adjustment: No Indication HCQ: Rheumatic diseases as a whole (Systemic lupus erythematosus, Rheumatoid arthritis, Sjogren's syndrome...) 1.82 [0.72;4.63] C 14/194   7/171 21 194
ref
Total 3 studies 1.13 [0.47;2.74] 54 253
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Baalbaki, 2020Baalbaki, 2020 0.62[0.25; 1.57]334748%ROB confusion: seriousROB selection: criticalROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Mollerach, 2019Mollerach, 2019 3.87[0.07; 205.70]0125%ROB confusion: criticalROB selection: lowROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Cooper (controls unexposed, sick), 2014Cooper, 2014 1 1.82[0.72; 4.63]2119447%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Total (3 studies) I2 = 33% 1.13[0.47; 2.74]542530.210.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.13[0.47; 2.74]5425333%NABaalbaki, 2020 Mollerach, 2019 Cooper (controls unexposed, sick), 2014 3 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.13[0.47; 2.74]5425333%NABaalbaki, 2020 Mollerach, 2019 Cooper (controls unexposed, sick), 2014 3 Tags Adjustment   - No  - No 1.13[0.47; 2.74]5425333%NABaalbaki, 2020 Mollerach, 2019 Cooper (controls unexposed, sick), 2014 3 Indication HCQ   - Rheumatic diseases as a whole (Syst ...  - Rheumatic diseases as a whole (Systemic lupus erythematosus, Rheumatoid arthritis, Sjogren's syndrome...) 1.90[0.77; 4.69]212060%NAMollerach, 2019 Cooper (controls unexposed, sick), 2014 2   - Systemic lupus erythematosus (SLE)  - Systemic lupus erythematosus (SLE) 0.62[0.25; 1.57]3347 -NABaalbaki, 2020 1 All studiesAll studies 1.13[0.47; 2.74]5425333%NABaalbaki, 2020 Mollerach, 2019 Cooper (controls unexposed, sick), 2014 30.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 13651

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 1.13[0.47; 2.74]5425333%NABaalbaki, 2020 Mollerach, 2019 Cooper (controls unexposed, sick), 2014 3 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.01[0.32; 3.20]18194 -NACooper (controls exposed to TNF-I), 2014 10.510.01.0